

PRESS RELEASE

Ajinomoto Co., Inc.
15-1, Kyobashi 1-chome, Chuo-ku, Tokyo 104-8315, JAPAN

Ajinomoto Co., Inc. Invests in Surgical Nutrition Startup Enhanced Medical Nutrition Inc.

Reinforcing Commitment to Funding Healthcare Innovations That Improve Patient Outcomes

TOKYO, March 24, 2025 – Ajinomoto Co., Inc. (“Ajinomoto Co.”) announced that it has invested in Enhanced Medical Nutrition Inc. (“EMN”), a Canadian startup specializing in surgical nutrition. It is the latest startup investment project led by its corporate venture capital office in the U.S. Through this investment, Ajinomoto Co. will strengthen its commitment to further improving nutritional issues for patients, in addition to its current medical food business focusing on the U.S., U.K. and Ireland.

Nutritional care for surgery patients before and after operation is becoming a growing concern^{*1}. Malnutrition is linked to increased rates of post-operative complications and longer hospital stays. In spite of this, dietary intake often remains inadequate among surgery patients. Two out of every three patients undergoing major surgery are malnourished before their operation, according to a study by the U.S. National Institute of Health^{*2}.

^{*1} Source: 2018 European Review for Medical and Pharmacological Sciences,

[*Impact of patients nutritional status on major surgery outcome*](#)

^{*2} Source: 2019 U.S. National Institute of Health,

[*The Malnourished Surgery Patient: A Silent Epidemic in Perioperative Outcomes?*](#)

EMN commercializes evidence-based products to support post-surgery physical recovery, and is dedicated to pioneering a new standard of care where nutrition therapy is leveraged to reduce risks of complications, accelerate recovery, and enhance overall patient outcomes. EMN currently focuses on serving orthopedics patients, targeting a nutritional market estimated to be approximately USD 1.94 billion^{*3}. The most common orthopedic surgeries include knee and hip replacements, and their demand is growing due to unprecedented population aging.

^{*3} Based on estimation by Ajinomoto Co.



ENROUTE®, EMN's surgical nutrition program

This investment underlines Ajinomoto Co.'s interest in the growing need for nutritional supplementation in improving the care of vulnerable populations. Ajinomoto Co. already holds a strong position in medical nutrition products and research. Its expanding business includes therapeutic nutrition for inborn errors of metabolism, ketogenic diet therapy, disease-related malnutrition, and severe protein allergy, all through its US subsidiary Ajinomoto Cambrooke, Inc. (ACI). It also includes life-enhancing oral nutritional supplements^{*4} particularly for older adults through Nualtra Ltd., its subsidiary based in the U.K. and Ireland. The Ajinomoto Group is consistently looking for opportunities to invest in elevating the quality of life of patients who will benefit from targeted dietary therapy. Leveraging the Group's combined knowledge and expertise in medical nutrition, its commitment to EMN will further accelerate the recovery of the growing number of patients undergoing joint replacement surgery.

^{*4} ONS: Products positioned between medical products and dietary supplements

Ajinomoto Co.'s mission is to contribute to the well-being of all human beings, our society and our planet with "AminoScience." To support this goal, the company will continue to search for partnerships with academia and medical providers to explore the role of amino acids in extending healthy lifespan of people. From nutritional support for muscle function and mobility to platform technologies that enable next-generation pharmaceutical solutions, Ajinomoto Co. is advancing preventions and treatments that contribute to longer, healthier lives.

Reference



■ Overview of Enhanced Medical Nutrition Inc.

- (1) Location: Ontario, Canada
- (2) Establishment: 2016
- (3) Representative: Eric Zimmerman, CEO
- (4) Business description: Development and sales of nutritional products
- (5) Number of employees: 21
- (6) Website: <https://www.emn.health/>

■ Overview of Ajinomoto Cambrooke, Inc.

- (1) Location: Massachusetts, United States of America
- (2) Establishment: 2000 (as Cambrooke Therapeutics, Inc.)
- (3) Representative: Rick Jentis, President
- (4) Business description: Manufacture and sales of medical foods
- (5) Number of employees: 124
- (6) Website: <https://www.cambrooke.com/>

■ Overview of Nualtra Ltd.

- (1) Location: Limerick County, Ireland
- (2) Establishment: 2012
- (3) Representative: Mark Lane, CEO
- (4) Business description: Manufacture and sale of ONS product
- (5) Number of employees: 26
- (6) Website: <https://nualtra.com/>

The Ajinomoto Group will contribute to the well-being of all human beings, our society and our planet with "AminoScience" based on the corporate slogan "Eat Well, Live Well.". The Ajinomoto Group has offices in 34 countries and regions, and sells products in more than 130 countries and regions. In fiscal 2023, sales were 1.4392 trillion yen (9.9 billion U.S. dollars). To learn more, visit www.ajinomoto.com.

For further information, please contact: [HERE](#)